01:39 PM EDT, 07/31/2026 (MT Newswires) -- Replimune ( REPL ) stock soared 94% after the company late Thursday reported a favorable outcome of the US Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in advanced melanoma.

The committee voted 10 to 3 that the efficacy results from the IGNYTE study are evaluable and clinically meaningful, it said.

After the outcome, Cantor Fitzgerald upgraded Replimune ( REPL ) to overweight from neutral.

More than 23.4 million shares traded intraday, compared with a daily average of about 5.85 million.

CareDx ( CDNA ) reported Q2 non-GAAP earnings and revenue late Thursday that beat market expectations. The company also lifted its 2026 revenue guidance.

Shares jumped 13%, with intraday trading volume rising to more than 1.3 million from a daily average of about 905,000.

Amazon's ( AMZN ) web services cloud-computing unit reported overnight the fastest sales growth in 18 quarters, helping the e-commerce giant handily exceed market expectations for Q2 earnings and revenue.

Shares advanced 15% amid a rise in intraday trading volume to over 84.7 million from a daily average of roughly 48.2 million.

Price: 10.62, Change: +5.21, Percent Change: +96.30